← Eichor
Study identifier: NCT04073290 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

Condition: Hepatic Encephalopathy · Cirrhosis, Liver · Portal Hypertension  ·  Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

PhasePhase 4
Planned participants238
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration as minimal HE (MHE), covert HE (grade I), or overt HE (OHE, grade II-IV). Liver cirrhosis is the most common cause of portal hypertension (PH). Patients who develop complications of PH, like variceal bleeding or refractory ascites, can benefit from a Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement. Unfortunately, post-TIPS HE is a common and often severe complication. Incidence of new onset or worsening of HE after TIPS is approximately 20-45%. Currently there is no strategy to prevent post-TIPS HE.

This description comes directly from the study's public registry record.

Talk to the study team

Koos de Wit, MD  ·  0031-20-5668468  ·  leverresearch@amc.uva.nl

Always discuss trial participation with your own doctor first.

Locations (6)

Universitaire Ziekenhuizen LeuvenLeuven, BelgiumRecruiting
Academic Medical CentreAmsterdam, NetherlandsRecruiting
University Medical Center GroningenGroningen, NetherlandsRecruiting
Leiden University Medical CenterLeiden, NetherlandsRecruiting
Radboud UniversityNijmegen, NetherlandsRecruiting
Erasmus Medical CenterRotterdam, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04073290